Literature DB >> 22529260

Bevacizumab advanced melanoma (BEAM) was a positive trial.

David R Minor.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22529260     DOI： 10.1200/JCO.2012.41.7477

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Inhibition of angiogenesis for the treatment of metastatic melanoma.

Authors:  Aaron S Mansfield; Svetomir N Markovic
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 2.  Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.

Authors:  Asmaa E El-Kenawi; Azza B El-Remessy
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

3.  In vitro and in ovo experimental study of two anti-VEGF agents used in ophthalmology.

Authors:  Mădălina Casiana Palfi; Ovidiu Muşat; Edward Paul Şeclăman; Mihnea Munteanu; Adina Iuliana Milcu; Andreea Iordache; Alina Dolghi; Sînziana Luminiţa Istrate; Ileana Ramona Barac; Veronica Mădălina Borugă
Journal:  Rom J Morphol Embryol       Date:  2021 Jul-Sep       Impact factor: 0.833
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.